Physician profile
Alejandro Polania
NPI 1750871299
$893.24
in general payments reported to CMS, 2019-2025
14 companies · $85.63 in 2025
The $85.63 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $174 · 2022: $205 · 2023: $273 · 2024: $156 · 2025: $85.63.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $514.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $195.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $167.46 | 2021-2024 | Wainua, Farxiga |
| Amgen INC. | $92.89 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $86.10 | 2022-2023 | Camzyos |
| Abiomed | $69.35 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $46.84 | 2023-2024 | Xarelto |
| Kiniksa Pharmaceuticals, LTD. | $45.43 | 2022-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $38.29 | 2022-2024 | Amvuttra |
| Boston Scientific Corporation | $38.24 | 2023 | Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.31 | 2024 | Lifevest |
| Pfizer INC. | $21.50 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.42 | 2022 | |
| B. Braun Interventional Systems INC. | $19.17 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.42 | 2024 | Uptravi, Opsumit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Polania listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.